Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	6.10T +35.6%
Revenue (ttm)	1.66T +12.9%
Net Income	217.04B +102.2%
EPS	17,098.38 +102.0%
Shares Out	12.69M
PE Ratio	28.10
Forward PE	26.81
Dividend	2,000.00 (0.42%)
Ex-Dividend Date	Mar 30, 2026

Volume	274,223
Open	526,000
Previous Close	534,000
Day's Range	475,000 - 526,000
52-Week Range	302,000 - 647,000
Beta	0.53
Analysts	Buy
Price Target	664,545.45 (+38.3%)
Est. Earnings	Oct 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,338
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Analyst Summary

According to 11 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩664,545, which is an increase of 38.30% from the latest price.

Price Target

₩664,545

(38.30% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 10, 2026

Data Sources Report a data error